# ARNOLD & PORTER LLP



202.942.5000 202.942.5999 Fax

555 Twelfth Street, NW Washington, DC 20004-1206

May 27, 2005

Mail Stop After Final Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Application No. 09/227,881

Filed:

January 11, 1999

Title:

Nucleic Acids, Kits and Methods for the Diagnosis,

Prognosis and Treatment of Glaucoma and Related

Disorders

Applicants:

NGUYEN et al.

Atty. Docket: 16491.066

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

- 1. an Amendment and Reply;
- 2. a Terminal Disclaimer over U.S. Patent;
- 3. an Interview Summary;
- 4. a Petition for Extension of Time; and
- 5. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

Applicants request that the following fees be charged to Deposit Account No. 50-2387 referencing docket number 16491.066:

> one-month extension of time fee \$ 120.00

\$ 130.00 Terminal Disclaimer fee

## ARNOLD & PORTER LLP

Commissioner for Patents Atty. Docket: 16491.066

Page 2

In the event that extensions of time beyond those petitioned for herewith are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any fees, other than the one month extension of time (\$120.00) and the Terminal Disclaimer (\$130.00), are due in conjunction with this filing. However, if any additional fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387 referencing matter number 16491.066. A duplicate copy of this letter is enclosed.

Respectfully submitted,

Joel M. Freed (Reg. No. 25,101)

David R. Marsh (Reg. Attorney No. 41,408) Joseph W. Ricigliano (Reg. Agent No. 48,511)

**Enclosures** 



#### THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thai D. Nguyen et al.

Appln. No.: 09/227,881 Confirmation No.: 7578 Filed: January 11, 1999

For: Nucleic Acids, Kits and Methods for the Diagnosis, Prognosis and Treatment of

Glaucoma and Related Disorders

Group Art Unit: 1635

Examiner: Schultz, James D.

Docket No.: 16491.066

### **Interview Summary**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Interview of April 26, 2005, Applicants representative submits the following summary.

#### Telephonic Interview, in Attendance:

Assistant Examiner: James D. Schultz

Supervisory Patent Examiner: Andrew Wang

Registered Patent Agent: Joseph W. Ricigliano

1) Exhibits: None

2) Claims Discussed: 144-174.

3) Cited Art Discussed: None

4) Amendments discussed: None

- 5) <u>Summary</u>: Applicant's representative and the Examiners discussed the election/ restriction, the rejections under 35 USC §§ 102, 112 and 132, and the possible allowance of claims 145, 148-150, 154, 156, 161, and 165-174.
- 6) Other Matters: The filing of a terminal disclaimer to overcome the non-statutory double patenting rejection.
- 7) General Result: The Examiners indicated that they would be amenable to the withdrawal of the remaining rejections and objections, and would permit the application to pass to allowance, provided that the claims rejected Under 35 U.S.C. § 102 were cancelled and a suitable terminal disclaimer was filed.

Respectfully submitted,

Joel M. Freed (Reg. Attorney No. 25,101)

David R. Marsh (Reg. Attorney No. 41,408)

Joseph W. Ricigliano (Reg. Patent Agent No. 48,511)

Date: May 27, 2005 ARNOLD & PORTER LLP 555 12<sup>th</sup> Street, N.W. Washington, DC 20004 202.942.5000 telephone 202.942.5999 facsimile